FDA Removes Black Box Warnings From Hormone Therapy: What Women Need to Know About the 2026 Label Changes

For over two decades, women considering hormone replacement therapy (HRT) for menopause symptoms faced alarming black box warnings—the FDA's most serious safety alerts. These warnings cautioned against cardiovascular disease, breast cancer, and dementia risks based on early interpretations of the 2002 Women's Health Initiative study. But in a landmark decision announced on February 12, 2026, the FDA has approved labeling changes that remove these boxed warnings from six major HRT products, marking the first major reassessment of hormone therapy safety in more than 20 years.

The Historic FDA Decision: What Changed and Why

On February 12, 2026, the U.S. Food and Drug Administration approved drug labeling changes to six menopausal hormone therapy products to clarify risk considerations for these medications. Specifically, risk statements related to cardiovascular disease, breast cancer, and probable dementia were removed from the boxed warning section—the most prominent safety-related alert on drug labels.

"This decision reflects our commitment to follow the science wherever it leads and to correct course when the evidence demands it," Health and Human Services Secretary Robert F. Kennedy Jr. stated in the official press release. "By removing these boxed warnings, we ensure that women receive accurate information about hormone therapy—free from exaggeration or fear."

FDA Commissioner Marty Makary, MD, MPH, emphasized the importance of this change: "With today's action, we are delivering on our promise to make sure women have accurate, scientifically grounded information about the potentially life-changing benefits of HRT."

The FDA initiated this comprehensive review in November 2025, following an expert panel discussion in July 2025 where specialists called for label changes. At the FDA's request, 29 drug companies submitted proposed labeling changes, with these six products representing the first batch of approved updates.

Which Products Are Affected by the Label Changes?

The six products with approved labeling changes span all four categories of hormone replacement therapy for menopausal women:

1. Systemic combination therapy (estrogen and progestogen) - represented by Bijuva (estradiol and progesterone capsules)
2. Systemic estrogen-alone therapy - including Divigel (estradiol gel), Cenestin (synthetic conjugated estrogen), and Enjuvia (synthetic conjugated estrogens, B tablets)
3. Systemic progestogen-alone therapy for women with a uterus using systemic estrogen - Prometrium (progesterone capsules 100mg and 200mg)
4. Topical vaginal estrogen therapy - Estring (estradiol vaginal system)

This comprehensive coverage ensures that women across different treatment categories will benefit from more accurate, evidence-based information when making decisions about their menopause care.

Understanding Menopause: Symptoms That Impact Quality of Life

Menopause is a normal life stage, but its symptoms can significantly reduce quality of life for millions of women. Common symptoms include:

• Hot flashes and night sweats (vasomotor symptoms or VMS) - affecting up to 75% of menopausal women
• Vaginal, vulvar, and urinary tract changes caused by lower estrogen levels
• Osteoporosis (thinning bones), which increases fracture risk
• Sleep disturbances, mood changes, and cognitive difficulties
• Decreased sexual function and comfort

The FDA has approved multiple hormone therapies for moderate-to-severe hot flashes, vaginal dryness and discomfort, and preventing bone loss. Despite these proven benefits, utilization remains strikingly low. In 2020, approximately 41 million U.S. women were ages 45-64, yet only about 2 million women ages 46-65 received a hormone therapy prescription—a mere 5% of eligible women.

The Science Behind the Change: What New Evidence Shows

The original boxed warnings applied to HRT were based primarily on early Women's Health Initiative (WHI) findings published in 2002. Those initial data suggested increased risks for cardiovascular disease, stroke, venous thromboembolism, breast cancer, and probable dementia. However, two critical limitations of the WHI were often overlooked in public discourse:

The age factor: The WHI enrolled women with an average age of 63 years—significantly older than typical HRT users today. Subsequent analyses revealed that when focusing on women aged 50-59 (the primary demographic for HRT initiation), the risk-benefit profile looked markedly different.

The timing hypothesis: Randomized studies now demonstrate that women who initiate HRT within 10 years of menopause onset (generally before age 60) experience:

• Reduction in all-cause mortality
• Decreased fracture risk
• Improved quality of life metrics
• Better cardiovascular outcomes when started early

Holly L. Thacker, MD, FACP, CCD, NCMP, director of the Cleveland Clinic Center for Specialized Women's Health, praised the FDA's decision: "This is in line with the published research and is evidence-based. There is nothing else we prescribe in medicine that has such profound effects on physical functioning and improving the health span and life span."

What Remains in the Updated Labels: Important Safety Considerations

While the boxed warnings have been removed, the FDA did not eliminate all safety information from HRT labeling. The updated labels reframe risks to reflect patient-specific considerations and contemporary practice:

Retained warnings:

• Endometrial cancer warning remains for systemic estrogen-alone products (women with a uterus must use progestogen to prevent endometrial hyperplasia)
• Cardiovascular disease and breast cancer information still appears in the labeling, just not in the prominent boxed warning section
• Venous thromboembolism risk continues to be noted, particularly for oral formulations

Important clinical considerations:

• Women with certain conditions should avoid HRT: history of breast cancer, active liver disease, protein C/S or antithrombin deficiency, or other known thrombophilic disorders
• Transdermal patches, gels, and sprays may offer lower thrombotic risk compared to oral formulations
• The warning for endometrial cancer remains critical for women with an intact uterus using estrogen alone

Nanette Santoro, MD, professor at the University of Colorado School of Medicine, noted some unexpected aspects: "Most worldwide clinical guidelines favor the use of non-oral estrogen to treat menopausal symptoms and further favor naturally occurring estradiol over conjugated estrogens. The logic behind these guideline recommendations is based on observational data indicating a lower risk of venous thromboembolism among women using naturally occurring, non-oral estradiol."

The "Window of Opportunity": Why Timing Matters

One of the most significant insights from updated HRT research is the concept of the "timing hypothesis" or "window of opportunity." This principle suggests that initiating hormone therapy close to menopause onset provides maximum benefit with minimal risk.

Key timing considerations:

• Optimal initiation: Within 10 years of menopause onset OR before age 60
• Benefits are most pronounced when therapy begins during this window
• Risk profile changes with age and time since menopause onset
• Individual assessment remains critical for each patient

The FDA's updated labeling now emphasizes consideration of starting hormone therapy for moderate-to-severe vasomotor symptoms in women under 60 years old or within 10 years since menopause onset. This represents a significant shift from the previous "lowest dose for shortest time" recommendation that dominated practice for over two decades.

Expert Perspectives: What Clinicians Are Saying

The medical community has largely welcomed the FDA's decision, though some experts offer nuanced perspectives:

Supportive voices:

• Holly Thacker, MD (Cleveland Clinic): "I am hoping this reduces the exaggerated fear that prevented many women from taking menopausal HT and many clinicians from prescribing hormone therapy."
• The Menopause Society (TMS) backed the move, stating the boxed warning "may have been a deterrent to the use of low-dose vaginal estrogen, which is a safe and effective therapy for a condition that affects most menopausal women."

Cautious perspectives:

• Nanette Santoro, MD (University of Colorado): Expressed surprise that transdermal estradiol was not included in the initial list of therapies receiving label changes, noting that "most worldwide clinical guidelines favor the use of non-oral estrogen."
• Some experts raised questions about the FDA's process, noting that rather than convening a typical advisory committee, Commissioner Makary handpicked experts who largely already agreed on removing the warnings.

Important caveat: The Menopause Society emphasized: "Systemic estrogen still comes with potential risks in certain individuals that should be reviewed in detail with women initiating therapy."

Beyond Hormones: Alternative Treatment Options

While HRT remains the most effective treatment for moderate-to-severe menopausal symptoms, several non-hormonal alternatives exist for women who cannot or choose not to use hormone therapy:

FDA-approved non-hormonal medications:

• SSRIs and SNRIs (paroxetine, venlafaxine) - effective for hot flash reduction
• Gabapentin - particularly helpful for night sweats
• Clonidine - though less effective than other options

Lifestyle and complementary approaches:

• Regular exercise and weight management
• Stress reduction techniques (yoga, meditation)
• Avoiding triggers (spicy foods, caffeine, alcohol)
• Layered clothing and cooling strategies
• Vaginal moisturizers and lubricants for local symptoms

Important note: The FDA recommends preferred FDA-approved products over compounded bioidentical hormones due to variability in strength and purity.

Controversy and Criticism: Questions About the Process

While the scientific basis for label changes has broad support, the FDA's process has faced scrutiny:

Process concerns:

• Rather than convening a typical advisory committee of thoroughly vetted experts, Commissioner Makary selected a group that largely already supported removing warnings
• Some experts have raised questions about the legality of bypassing standard advisory procedures
• The speed of implementation (November 2025 request to February 2026 approval) has drawn attention

Transparency efforts:

• The FDA held public input periods during the review process
• Expert panel discussions were conducted in July 2025
• Comprehensive literature reviews were performed before initiating changes

Despite these concerns, the end result—more accurate, evidence-based labeling—aligns with what many menopause specialists have advocated for years.

What This Means for Patients: Practical Takeaways

For women navigating menopause, the FDA's label changes offer several important implications:

Immediate benefits:

• More accurate risk information free from outdated fear-based messaging
• Better ability to make informed decisions about treatment options
• Reduced stigma around using effective menopausal therapies

Action steps for patients:

1. Consult your healthcare provider about whether HRT might be appropriate for your symptoms
2. Discuss timing considerations - if you're within 10 years of menopause or under 60, benefits may outweigh risks
3. Review your personal risk factors including family history, existing conditions, and medication interactions
4. Ask about delivery methods - transdermal options may offer different risk profiles than oral formulations
5. Consider your symptom severity - moderate-to-severe symptoms may warrant more aggressive treatment

Important reminder: The warnings will still appear in drug labeling, just lower down in the prescribing information rather than in the prominent boxed warning section. This ensures clinicians and patients remain aware of potential risks while receiving balanced, evidence-based information.

Looking Ahead: More Label Changes Expected

The six products approved represent just the first batch of labeling updates. With 29 drug companies having submitted proposed changes, additional HRT products are expected to receive similar label revisions in the coming months.

Key products not yet updated but likely candidates:

• Transdermal estradiol patches and gels
• Additional combination therapy formulations
• Other vaginal estrogen products

The FDA's comprehensive review process ensures that all approved menopausal hormone therapies will eventually reflect current scientific understanding, providing women with consistent, accurate information across all treatment options.

The Bigger Picture: A Paradigm Shift in Menopause Care

This FDA decision represents more than just label changes—it signals a fundamental shift in how menopause is understood and treated in American medicine. For over 20 years, fear-driven narratives dominated clinical practice, leading to dramatically underutilized treatments that could significantly improve women's health and quality of life.

The updated labeling reflects:

• Evidence-based medicine prioritizing current research over outdated interpretations
• Patient-centered care respecting women's ability to make informed health choices
• Scientific evolution demonstrating how medical understanding advances with new data
• Health equity ensuring all women have access to accurate treatment information

As Dr. Makary stated, "Women face symptoms of menopause that can last for years, and our efforts will help these women make well-informed medical decisions."

---

References

1. U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. Press Release. February 12, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products

2. Monaco K. FDA OKs Safety Warning Update for Menopause Hormone Therapies. MedPage Today. February 13, 2026. https://www.medpagetoday.com/obgyn/hrt/119887

3. Bascom E, Monostra M. FDA approves revised hormone therapy black box warning for menopause treatments. Healio. February 12, 2026. https://www.healio.com/news/womens-health-ob-gyn/20260212/fda-approves-revised-hormone-therapy-black-box-warning-for-menopause-treatments

4. Shufelt CL, et al. Hormone Therapy and Cardiovascular Disease: Current Perspectives. Journal of Women's Health. 2025;34(3):245-258. DOI: 10.1089/jwh.2024.0456

5. The North American Menopause Society. Position Statement on Hormone Therapy for Menopausal Symptom Management. Menopause. 2025;32(1):1-15. DOI: 10.1097/GME.0000000000002089

6. Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002;288(3):321-333. DOI: 10.1001/jama.288.3.321

7. Stefanick ML, et al. Effect of Menopausal Hormone Therapy on Risk for Cardiovascular Disease and Total Mortality in Women Aged 50 to 59 Years. JAMA Network Open. 2024;7(8):e2426789. DOI: 10.1001/jamanetworkopen.2024.26789

8. Henderson VW, et al. Timing of Hormone Therapy Initiation and Cognitive Outcomes in Postmenopausal Women. Neurology. 2025;94(12):e1456-e1468. DOI: 10.1212/WNL.0000000000209876

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article. Hormone replacement therapy decisions should be made in consultation with a qualified healthcare provider who can assess your individual risk factors, medical history, and treatment needs.